A5076233106- Wound Healing and Treatments
- Diabetic Foot Ulcer Assessment and Management
- Mesenchymal stem cell research
- Diagnosis and Treatment of Venous Diseases
- Pressure Ulcer Prevention and Management
Abstract Background While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly standard treatment. GMP-manufactured skin-derived ABCB5 + mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing engraftment potential, ability adaptively inflammatory signals, healing-promoting efficacy in mouse models human chronic venous...
A significant number of chronic venous ulcers (CVUs) fail to heal despite guideline-conform standard care. Skin-derived ABCB5+ mesenchymal stem cells (MSCs) can dampen the sustained IL-1β-driven inflammation present in wounds. Based on their wound healing-facilitating effects a mouse CVU model and an autologous first-in-human study, MSCs have emerged as potential candidate for cell-based advanced therapy non-healing CVUs. In interventional, multicenter, single-arm, phase I/IIa clinical...
Abstract Background While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly standard treatment. GMP-manufactured skin-derived ABCB5 + mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing engraftment potential, ability adaptively inflammatory signals, healing-promoting efficacy in mouse models human chronic venous...